Loading…
MannKind Corporation is projected to rise to $4.69 by 2027, a +20% move from its current price of $3.91. MNKD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $3.78 | $3.91 | $4.04 | 0.00% |
| Aug 3 | $3.73 | $3.91 | $4.10 | 0.00% |
| Aug 4 | $3.69 | $3.91 | $4.14 | +0.01% |
| Aug 5 | $3.66 | $3.91 | $4.18 | +0.01% |
| Aug 6 | $3.63 | $3.91 | $4.21 | +0.01% |
| Aug 7 | $3.61 | $3.91 | $4.24 | +0.01% |
| Aug 8 | $3.58 | $3.91 | $4.27 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.58 | $3.91 | $4.27 | +0.02% |
| Week 2 | $3.46 | $3.91 | $4.42 | +0.03% |
| Week 3 | $3.36 | $3.91 | $4.55 | +0.05% |
| Week 4 | $3.29 | $3.91 | $4.66 | +0.06% |
| Week 5 | $3.22 | $3.91 | $4.75 | +0.08% |
| Week 6 | $3.16 | $3.91 | $4.84 | +0.09% |
| Week 7 | $3.11 | $3.91 | $4.93 | +0.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MannKind Corporation is a healthcare company focused on transforming chronic disease care. It develops and commercializes treatments addressing unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Its products include Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its other products include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease.
The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MannKind Corporation (MNKD) is a healthcare stock currently trading at $4.13 with a market cap of $1.28B and a rank of 2213.
The near-term picture shows a neutral stance with price trading around a mix of trend signals, while the longer-term forecast points to a bullish trajectory, with the 2026 average near $4.13 and the 2050 average near $43.52, implying notable upside from current levels.
Key forecast milestones include 2027 average $4.84 and 2028 average $5.25, building toward 2030 average $8.54 and ultimately 2050 average $43.52. The trajectory carries increasing upside potential, with 2030 max $12.67 and 2040 max $33.23, culminating in 2050 max $83.62.
Overall, the outlook suggests upside potential across years, with the 2026 year showing a 0% ROI, then rising to double-digit percentages in subsequent years and into triple digits by mid-century.
A major floor 41.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.8% away) — a key level to hold.
The nearest ceiling, 15.6% above — a clean break opens room to run.
A major ceiling 22.0% above — clearing it would confirm fresh momentum.
Key MNKD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MNKD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.95 | Sell | $3.96 | Sell |
| MA 10 | $3.96 | Sell | $3.97 | Sell |
| MA 20 | $4.03 | Sell | $3.98 | Sell |
| MA 50 | $3.86 | Buy | $3.84 | Buy |
| MA 100 | $3.31 | Buy | $3.82 | Buy |
| MA 200 | $4.33 | Sell | $4.08 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.50 | Neutral |
| Stoch RSI (14) | 26.76 | Neutral |
| CCI (20) | -77.56 | Neutral |
| Williams %R (14) | -75.86 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -4.40 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 24.14 | Neutral |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 50.94 | Neutral |
| Momentum (10) | -0.12 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 3.95 | Sell |
| ADX (14) | 11.34 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is Neutral. RSI14 is 50, indicating balanced momentum.
Price is around the SMA50 of $3.76 and below the SMA200 of $4.37, suggesting a mixed near-term trend with key levels nearby.
The thirty-day range spans $3.38 to $5.04, with support at $3.63 and resistance at $4.52. Annualized volatility is 60%, underscoring notable near-term variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.28 | $3.91 | $4.98 | 0% | Neutral | |
| $3.67 | $4.69 | $6.38 | +20% | Neutral | |
| $3.97 | $5.26 | $7.47 | +34% | Bullish | |
| $4.91 | $6.69 | $9.84 | +71% | Bullish | |
| $6.39 | $8.92 | $13.50 | +128% | Bullish | |
| $6.77 | $9.68 | $15.01 | +148% | Bullish | |
| $6.97 | $10.18 | $16.15 | +160% | Bullish | |
| $7.35 | $10.97 | $17.75 | +181% | Bullish | |
| $7.82 | $11.91 | $19.62 | +205% | Bullish | |
| $8.90 | $13.81 | $23.13 | +253% | Bullish | |
| $13.07 | $22.10 | $39.73 | +465% | Bullish | |
| $26.82 | $52.90 | $105.25 | +12.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.28 | $3.91 | $4.61 | +0.00% |
| September 2026 | $3.15 | $3.76 | $4.61 | -3.96% |
| October 2026 | $3.26 | $3.92 | $4.87 | +4.33% |
| November 2026 | $3.32 | $4.01 | $5.04 | +2.40% |
| December 2026 | $3.23 | $3.93 | $4.98 | -2.05% |
Click any year to see its month-by-month MNKD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MNKD to range from $2.28 to $4.98 through 2026. The $3.91 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The MNKD price prediction for 2027 points to an average of $4.69 (low $3.67, high $6.38) — a potential gain of +20% on today's $3.91. Price action looks broadly range-bound.
In 2028, MNKD is projected to trade between $3.97 and $7.47, averaging $5.26 — a potential gain of +34% from today's $3.91. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
MannKind Corporation's 2029 outlook centres on $6.69, within a $4.91 to $9.84 range. That is up +27% on the projected 2028 average. That marks a +71% change versus current levels. Momentum favours further upside here.
By 2030, MNKD could reach as high as $13.50, with a base case around $8.92 and support toward $6.39 — roughly +128% from $3.91. Buyers look set to stay in control over this stretch.
Expect MNKD to range from $6.77 to $15.01 through 2031. The $9.68 average target implies a +148% move from current prices. That is up +8% on the projected 2030 average. Momentum favours further upside here.
The MNKD price prediction for 2032 points to an average of $10.18 (low $6.97, high $16.15) — a potential gain of +160% on today's $3.91. Buyers look set to stay in control over this stretch.
In 2033, MNKD is projected to trade between $7.35 and $17.75, averaging $10.97 — a potential gain of +181% from today's $3.91. That is up +8% on the projected 2032 average. Momentum favours further upside here.
MannKind Corporation's 2034 outlook centres on $11.91, within a $7.82 to $19.62 range. That is up +9% on the projected 2033 average. That marks a +205% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, MNKD could reach as high as $23.13, with a base case around $13.81 and support toward $8.90 — roughly +253% from $3.91. Momentum favours further upside here.
Expect MNKD to range from $13.07 to $39.73 through 2040. The $22.10 average target implies a +465% move from current prices. That is up +60% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The MNKD price prediction for 2050 points to an average of $52.90 (low $26.82, high $105.25) — a potential gain of +12.5x on today's $3.91. Momentum favours further upside here.
Investing $1,000 in MNKD today (≈ 255.754476 MNKD) could be worth
$13,529.66
+$12,529.66 (+1253%) by 2050 · US Dollar
Based on the average projected MNKD price of $52.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MNKDwould be worth at today's price.
$1,000 invested in MNKD on Jul 31, 2025 (≈ 264.550267 MNKD) would be worth
$1,034.39
+$34.39 (+3.4%) today · 1.03× · US Dollar
Based on a MNKD entry price of $3.78 vs. today's $3.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.13 | $946.73 | -5.3% |
| 1 month ago | $4.05 | $965.43 | -3.5% |
| 3 months ago | $2.84 | $1,376.76 | +37.7% |
| 6 months ago | $6.01 | $650.58 | -34.9% |
| 1 year ago | $3.78 | $1,034.39 | +3.4% |
| All time (5.0y) ago | $4.03 | $970.22 | -3.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MNKD forecast.
Our base-case forecast reaches $7.80 around 2030.
Implied market cap at $7.80: $2.41B
The multi-year forecast points to a bullish trajectory across the horizon. In 2027 the average is $4.84, rising through 2028 at $5.25 and 2029 at $6.46, with 2030 average $8.54 and ROI of 106.7%. By 2031 the average is $9.06 and 2032 $9.45, continuing higher through 2033 at $10.28, 2034 $10.84, and 2035 $12.27, with cumulative upside reaching 197% by 2035.
The outlook then strengthens further: 2040 average $19.04 with a max of $33.23 and ROI of 361.1%; and by 2050 average $43.52 with a max of $83.62 and ROI of 953.8%.
These are estimates, not guarantees, and actual results can be influenced by market conditions, regulatory developments, and company-specific performance.
Tap a question to reveal the answer.
The 2030 forecast shows min $6.21, avg $8.54, max $12.67, with ROI 106.7% and sentiment BULLISH.
Forecasts show a bullish sentiment from 2027 onward, with 2027 avg $4.84, 2028 $5.25, 2029 $6.46, 2040 $19.04, and 2050 $43.52 average. ROI rises to 106.7% by 2030, 361.1% by 2040, and 953.8% by 2050. These are projections, not guarantees.
Yes. The 2035 forecast lists a max of $20.03, with earlier years’ maxs lower and 2030 max at $12.67. This indicates a potential pathway to $20 in 2035 on the upper end of the range.
Current price is $4.13 and market cap is $1.28B.
30-day range is $3.38–$5.04; RSI 14 is 50; SMA50 is $3.76; SMA200 is $4.37; support is $3.63 and resistance is $4.52; sentiment is Neutral and annualized volatility is 60%.
MannKind Corporation Community Discussion
0Share your MannKind Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.